Alphanate in Immune Tolerance Induction Therapy

Hemophilia A, Congenital Clinical Trial

Official title:

A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of Plasma-Derived Factor VIII/VWF (Alphanate®) in Immune Tolerance Induction Therapy in Subjects With Congenital Hemophilia A

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03095287
• Other study ID #: GBI1406
• Secondary ID: 2015-005524-26
• Status: Terminated
• Phase: Phase 2
• Start date: January 3, 2018
• Est. completion date: September 18, 2020

Study information

• Verified date: October 2021
• Source: Grifols Therapeutics LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, multinational, prospective, single-arm, nonrandomized, open-label study, planned in of approximately 25 male participants with congenital hemophilia A who will receive their first (primary) immune tolerance induction (ITI) treatment with alphanate. The study consists of 2 phases: - An ITI Treatment Phase in which all eligible participants will receive ITI treatment with alphanate for a period of up to 33 months. Upon confirmation of complete immune tolerization, participants will then enter a 12-month Prophylactic Phase. If, after 33 months of ITI, a participants has achieved partial immune tolerance, the participants will enter a 12-month Prophylactic Phase. - A 12-month Prophylactic Phase for all participants who meet the criteria for complete or partial success to continue on a prophylactic dosing regimen of alphanate. Due to limited enrollment, this study was early terminated.

Description:

Male participants <12 years of age with an inhibitor titer >0.6 to <10 Bethesda Units (BU) will be screened before the planned start of ITI treatment. Participants continuing to meet the entrance criteria will enter the ITI Treatment Phase and receive daily doses of alphanate 100 IU/kg/day for up to 33 months, with a one-time option to increase to a dosing regimen of 200 IU/kg/day at any time after 90 days of ITI treatment. Participants will continue to receive their daily alphanate dose for up to 33 months until the titer is negative (<0.6 BU) on 2 consecutive assessments and treatment success is confirmed by FVIII:C pharmacokinetic assessments, at which time they will enter the 12-month Prophylactic Phase. In addition, participants who have achieved partial immune tolerance at the completion of 33 months of ITI treatment will enter the 12-month Prophylactic Phase. Participants who do not achieve partial immune tolerance at the completion of 33 months of ITI treatment will be discontinued as treatment failures. The Prophylactic Phase begins with an 8-week taper period for participants tolerized with 100 IU/kg/day or with a 12-week taper period for participants tolerized with 200 IU/kg/day to bring the dose down in a step-wise manner to a prophylactic dose of alphanate 50 IU/kg every other day or 3 times per week, at the investigator's discretion. During the Prophylactic Phase, participants will be monitored monthly for the first 4 months and then every 2 months for the remaining 8 months to assess sustainability of immune tolerance. Due to limited enrollment, this study was early terminated.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: September 18, 2020
• Est. primary completion date: September 18, 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A to 12 Years

Eligibility

Inclusion Criteria:

• The subject has a documented diagnosis of severe congenital hemophilia A with FVIII:C <1% of normal.
• The subject is a male <12 years (and at least 2 years of age if in India) at the Baseline Visit.
• The subject's documented historical peak inhibitor titer is =5 BU and =200 BU.
• The subject has an inhibitor titer >0.6 BU and <10 BU at Screening.
• The subject has had a delay =24 months from the date of diagnosis of the inhibitor to the start of the subject's ITI treatment.

Exclusion Criteria:

• The subject has acquired factor VIII (FVIII) deficiency.
• The subject has previously received ITI treatment.
• The subject has a recent (within 1 month) history of central line infection at the time of Screening.
• The subject has a high risk of cardiovascular, cerebrovascular, or thromboembolic event as judged by the investigator.
• The subject is currently undergoing treatment with immunosuppressive drugs (eg, systemic corticosteroids), azathioprine, cyclophosphamide, high dose immunoglobulin, interferon, or the use of a protein A column or plasmapheresis and is unwilling to discontinue these treatments starting at the screening visit.
• The subject has a known infection with human immunodeficiency virus (HIV) or has clinical signs and symptoms consistent with current HIV infection.
• The subject has a known previous infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) or has clinical signs and symptoms consistent with current HBV or HCV infection.
• The subject has significant proteinuria, has a history of acute renal failure or severe renal impairment (blood urea nitrogen or creatinine >2 times the upper limit of normal), or is receiving dialysis at Screening.
• The subject has a value of aspartate transaminase or alanine aminotransferase >2 times the upper limit of normal at Screening.
• The subject has clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator, may interfere with successful completion of the trial or place the subject at undue medical risk.
• The subject has a history of anaphylaxis or severe systemic reaction to any plasma derived or other blood products.

Related Conditions & MeSH terms

• Hemophilia A
• Hemophilia A, Congenital

Intervention

Biological:
• Alphanate
Bolus IV injection.

Locations

Country	Name	City	State
Canada	McMaster Children's Hospital	Hamilton	Ontario
India	Lokmanya Tilak Municipal Medical College & General Hospital	Mumbai	Maharashtra
India	B. J. Govt. Medical College & Sassoon Hospital	Pune
Italy	Azienda Ospedaliera Universitaria Careggi	Firenze
Italy	A.O.U. Santa Maria della Misericordia Perugia	Perugia	Umbria
Italy	Universita degli Studi di Roma La Sapienza	Roma
Russian Federation	Kemerovo Regional Clinical Hospital	Kemerovo
Russian Federation	FGUs Hospital - Kirov Scientific Research Institute	Kirov
Russian Federation	Center for Hemophilia Treatment St.-Petersburg	Saint Petersburg
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Universitario Virgen del Rocio	Sevilla
Spain	Hospital Universitari i Politecnic La Fe	Valencia	Autonomous Community Of Valencia
United States	Emory University	Atlanta	Georgia
United States	University of North Carolina at Chapel Hill, Hemophilia and Thrombosis Center	Chapel Hill	North Carolina
United States	The Childrens Mercy Hospital	Kansas City	Missouri
United States	University of Kentucky	Lexington	Kentucky
United States	Childrens Hospital and Clinics of Minnesota	Minneapolis	Minnesota
United States	Robert Wood Johnson Medical Group	New Brunswick	New Jersey
United States	Newark Beth Israel Medical Center & Children's Hospital of New Jersey	Newark	New Jersey
United States	Seattle Children's Hospital, Seattle Children's Research Institute	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
Grifols Therapeutics LLC	Grifols Biologicals, LLC

Countries where clinical trial is conducted

United States,  Canada,  India,  Italy,  Russian Federation,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Treatment-emergent Adverse Events	Incidence of treatment-emergent adverse events during the ITI Treatment Phase and Prophylactic Phase	Up to 32.5 months
Primary	Percentage of Participants Who Achieved Complete Immune Tolerance Within 33 Months of Initiation of Immune Tolerance Induction (ITI) Treatment Phase	Complete immune tolerance was defined as the participants achieving 2 consecutive undetectable inhibitor titers (<0.6 BU) performed within 2 weeks of each other, Factor VIII activity (FVIII:C) in vivo plasma recovery =66% of the predicted normal value and FVIII:C half-life =6 hours after a 72-hour FVIII treatment-free period.	Up to 32.5 months
Secondary	Percentage of Participants Who Achieved Either Complete or Partial Immune Tolerance Within 33 Months of Initiation of ITI Treatment Phase	Complete immune tolerance was defined as the participants achieving 2 consecutive undetectable inhibitor titers (<0.6 BU) performed within 2 weeks of each other, Factor VIII activity (FVIII:C) in vivo plasma recovery =66% of the predicted normal value and FVIII:C half-life =6 hours after a 72-hour FVIII treatment-free period. Partial immune tolerance was defined as participants achieving reduction of inhibitor titer to <5 BU confirmed at 2 consecutive assessments within 2 weeks of each other, FVIII:C in vivo plasma recovery of <66% of the predicted normal value or FVIII:C half-life of <6 hours after a 72-hour FVIII treatment-free period and clinical response to FVIII therapy.	Up to 32.5 months
Secondary	Percentage of Participants Who Achieved Complete or Partial Immune Tolerance Without Relapse During the Prophylactic Phase	Relapse during the prophylactic phase for participants who have achieved complete immune tolerance was defined as a return of FVIII inhibitor titer to detectable levels (=0.6 BU) or FVIII:C recovery <66% of the predicted normal value or FVIII:C half-life <6 hours, confirmed by repeat assessment within approximately 2 weeks. Relapse for participants who have achieved partial immune tolerance was defined as an increase of FVIII inhibitor titer to =5 BU, confirmed by repeat assessment within approximately 2 weeks.	12 months during prophylactic phase
Secondary	Number of Bleeding Events During ITI Treatment Phase and Prophylactic Phase	Annualized frequencies of bleeding events during the ITI Treatment Phase and the Prophylactic Phase	Up to 32.5 months